Invasive lobular breast cancer

Invasive lobular breast cancer is the second most common type of breast cancer.

What is invasive lobular breast cancer?

Invasive lobular breast cancer means that the cancer started in the cells that line the lobules and has spread into the surrounding breast tissue. The lobules are the glands that make milk when breastfeeding.

Remember that if your doctor has told you that you have lobular carcinoma in situ (LCIS), you don't have invasive lobular breast cancer. These are two different things.

Lobular carcinoma in situ (LCIS)

About invasive lobular breast cancer

Invasive lobular breast cancer is the second most common type of breast cancer. Around 15 in every 100 breast cancers (around 15%) are invasive lobular carcinoma. This type can develop in women of any age. But it is most common in women between 45 and 55 years old.

Breast cancer is very rare in men. It is also very unusual for a man to have an invasive lobular type of breast cancer.


Invasive lobular breast cancer doesn't always form a firm lump. You are more likely to have a thickened area of breast tissue.

Possible symptoms include:

  • an area of thickening or swelling
  • a change in the nipple, for example it might turn inwards (become inverted)
  • a change in the skin, such as dimpling or thickening

While invasive lobular breast cancer can cause these particular symptoms, it’s worth being aware of the general symptoms of breast cancer.

Diagnosing invasive lobular breast cancer

In many women the cancer is found during breast screening. 

It’s important that you see your GP if you have any symptoms. They may refer you to a specialist breast clinic. At the breast clinic the doctor or specialist nurse takes your medical history and examines your breasts. They also feel for any swollen (enlarged) lymph nodes under your arms and at the base of your neck.

You have some of the following tests:

  • a mammogram (an x-ray of the breasts)
  • an ultrasound (if you are under 35 you are more likely to have an ultrasound scan instead of a mammogram)
  • a biopsy – a small sample of cells or tissue is taken from your breast and looked at under a microscope
  • a breast MRI scan – this scan uses magnetic fields to create images of the breast tissue

Treatment for invasive lobular breast

The treatment for invasive lobular breast cancer is the same as for the more common type of breast cancer (invasive breast cancer NST).

Usually, you have surgery to remove the area of cancer and a surrounding area of healthy tissue. This operation is called breast conserving surgery, or a wide local excision or lumpectomy

Invasive lobular breast cancer is sometimes found in more than one area within the breast. In that case, it might not be possible to remove just the area of the cancer. Your doctor may then recommend removal of the whole breast (a mastectomy).

If you choose to, you can have a new breast made (breast reconstruction) at the same time as mastectomy or some time afterwards.

After the surgery you might have: 

  • radiotherapy
  • chemotherapy
  • hormone therapy
  • targeted cancer drug therapy
  • drugs that help prevent or slow down bone thinning (osteoporosis) or bone damage
  • a combination of these treatments

You may have surgery to your armpit called a sentinel lymph node biopsy. This means having about 3-5 lymph nodes removed. Sometimes surgeons have to remove more lymph nodes. Your doctor will let you know whether you need this. 

You might have chemotherapy or hormone therapy before surgery called neoadjuvant therapy. The aim is to shrink the cancer down. This means that some people may be able to have breast conserving surgery, who may have needed removal of the breast (mastectomy). 

Your doctor considers many things before deciding the best treatment for you. This is why your treatment may be different from other people with breast cancer.

Follow up

After treatment you usually have regular check ups. At the check ups your doctor or a breast care nurse will examine you and ask about your general health. This is your chance to ask questions and to tell them if anything is worrying you.

How often you have check ups depends on your individual situation but they might go on for at least 5 years. This might include yearly mammograms. 

It’s important to remember that you can contact your doctor or nurse between appointments if you are concerned about a symptom or have questions. You don't have to wait for your next appointment. You can also speak to your GP.

In some hospitals you don't have regular appointments after treatment. But if you have new symptoms or are worried about anything you can phone your doctor or breast care nurse or make an appointment to see them. 

UK guidelines say that everyone who has had treatment for early breast cancer should have a copy of a written care plan. The care plan has information about tests you will have, and signs and symptoms to look out for. It will also include contact details for specialist staff, such as your breast care nurse.

Trials and research

There are many breast cancer trials.

Breast cancer research is looking at:

  • the causes and prevention of breast cancer
  • screening and diagnosis
  • new treatments
  • ways to improve existing treatments
  • ways to cope with cancer and its treatment
  • Early and locally advanced breast cancer: diagnosis and treatment
    National Institute for Health and Care Excellence, 2009 (updated July 2018)

  • Invasive lobular carcinoma of the male breast – a systematic review with an illustrative case study
    S Jenna-Lynn and Others
    Breast Cancer. Dove Medical Press,2017. Volume 9, Pages 337–345

  • Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implications
    R Barroso-Sousa and O Metzger-Filho
    Therapeutic Advances in Medical Oncology, 2016. Volume 8, Issue 4 Pages 261–266

  • Early Breast Cancer: ESMO Clinical Practice Guidelines

    F Cardoso and others

    Annals of oncology, 2019. Volume 30, Pages 1194-1220.

  • Male breast cancer is not congruent with the female disease
    IS Fentiman
    Critical reviews in oncology/haematology, 2016. Volume 101, Pages 119-124

Last reviewed: 
13 Feb 2020

Related links